Company Overview
On September 18, 2023, Fresh Tracks Therapeutics’ Board of Directors (the “Board”) unanimously approved the Company’s proposed liquidation and dissolution (the “Dissolution”) and a proposed plan of liquidation and dissolution (the “Plan of Dissolution”), subject to the approval of the Company’s stockholders. Fresh Tracks encourages all stockholders of record on October 17, 2023 who have not yet voted to submit their proxy as soon as possible by calling the Company’s proxy solicitor D.F. King at 800-769-4414 (or international: 914-218-4628). If we fail to obtain the required stockholder approval, we intend to seek dissolution through the judicial process in Delaware.
In connection with the Plan of Dissolution, effective October 2, 2023, the Company discontinued all clinical and preclinical development programs and terminated most of its employees, except for certain employees, consultants, and advisors who will supervise or facilitate the dissolution and wind down of the Company. The Board also appointed Albert N. Marchio, II, the Company’s then-current Chief Financial Officer, as the Company’s Chief Executive Officer and Chief Financial Officer, as well as a director and Chairman of the Board.
